文献速递肾癌与肾肿瘤

英国三级肾癌网络真实世界研究:高危透明细胞肾细胞癌术后辅助帕博利珠单抗的 uptake、安全性与肿瘤结局

Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network.
PubMed 文献 · Eur Urol Oncol · 2026-09-24

治疗组24个月无病生存率为69%(95%CI 55-87),总生存率为95%(95%CI 89-100);92%出现任何级别治疗相关不良事件,19%发生≥3级事件,23%因毒性停药。真实世界安全性与肿瘤结局与KEYNOTE-564试验一致。

要点

  • 符合KEYNOTE-564标准且医学适合的患者中,50%在个体化咨询后拒绝辅助帕博利珠单抗。
  • 治疗组24个月DFS为69%(95%CI 55-87),OS为95%(95%CI 89-100)。
  • 92%出现任何级别TRAEs,19%为≥3级,23%因毒性停药。

核心结论

  • 真实世界中辅助帕博利珠单抗的安全性和肿瘤结局与KEYNOTE-564试验报告一致。
  • 治疗决策应超越试验入组标准,结合经验证的风险工具、合并症和患者偏好进行个体化咨询与共享决策。

研究设计与样本

  • 129例医学上适合治疗,接受辅助帕博利珠单抗或监测;生存分析采用Kaplan-Meier法。

主要发现

  • 154例符合标准,129例医学适合,其中50%拒绝治疗。
  • 治疗组与监测组中位年龄分别为61岁和67岁(p < 0.001)。
  • 治疗组肿瘤坏死比例45% vs 监测组30%(p = 0.075)。
  • 按Leibovich评分高危疾病比例治疗组53% vs 监测组42%(p = 0.2)。
  • 治疗组24个月DFS为69%(95%CI 55-87),OS为95%(95%CI 89-100)。

关键数值与推荐

  • 任何级别TRAEs发生率为92%,≥3级TRAEs为19%。
  • 33%需要使用皮质类固醇,23%因毒性停止治疗。

临床怎么用

  • 辅助帕博利珠单抗可用于符合KEYNOTE-564标准的高危ccRCC术后患者,但需个体化咨询与共享决策。
  • 治疗决策应结合经验证复发风险工具、合并症及患者偏好,而非仅依据试验入组标准。

局限性

  • 回顾性、非随机设计。
  • 随访时间相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant pembrolizumab has become the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence after surgery. However, evidence regarding its uptake, safety, and oncological outcomes in routine clinical practice remains limited. OBJECTIVE: To assess the uptake, oncological outcomes, and safety of adjuvant pembrolizumab among patients eligible according to the KEYNOTE-564 criteria within a UK tertiary renal cancer network. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively reviewed patients with surgically treated ccRCC who were eligible for adjuvant pembrolizumab and whose cases were discussed at the multidisciplinary team (MDT) of a UK tertiary renal cancer network between November 2022 and April 2024. INTERVENTION: Following individualized counselling and shared decision-making, patients received adjuvant pembrolizumab or underwent surveillance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Study outcomes included discussion of treatment eligibility at the MDT, patients' and clinicians' joint decision regarding adjuvant pembrolizumab, the incidence and type of treatment-related adverse events (TRAEs), treatment discontinuation rate, and management strategies following disease recurrence. Oncological outcomes included disease-free survival (DFS) and overall survival (OS). Survival outcomes were estimated using the Kaplan-Meier method. RESULTS AND LIMITATIONS: Of 154 patients eligible for adjuvant pembrolizumab, 129 were medically fit to receive treatment, of whom 50% declined therapy following counselling. Patients treated with pembrolizumab were younger than those undergoing surveillance (median age 61 vs 67 yr; p < 0.001), had higher tumour necrosis (45% vs 30%; p = 0.075), and had high-risk disease according to the Leibovich score (53% vs 42%; p = 0.2). At 24 mo, the estimated DFS and OS among patients treated with adjuvant pembrolizumab were 69% (95% confidence interval [CI] 55-87) and 95% (95% CI 89-100), respectively. Regarding safety, 92% of treated patients experienced any-grade TRAEs, 19% experienced grade ≥3 TRAEs, 33% required corticosteroids, and 23% discontinued treatment because of toxicity. The retrospective, nonrandomized design and relatively short follow-up represent the main study limitations. CONCLUSIONS: The safety and oncological outcomes of adjuvant pembrolizumab in routine clinical practice within a UK tertiary renal cancer network were consistent with those reported in the KEYNOTE-564 trial. Treatment decisions should extend beyond trial-based eligibility and incorporate validated recurrence risk tools, comorbidities, and patient preferences through individualized counselling and shared decision-making.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sordelli F, Basile G, Roussel E, et al. Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network. Eur Urol Oncol. 2026. PMID: 42786043. doi:10.1016/j.euo.2026.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。